argenex SE $ARGX Shares Sold by AWM Investment Company Inc.

AWM Investment Company Inc. reduced its position in argenex SE (NASDAQ:ARGX) by 34.8% during the 2nd quarter, Holdings Channel.com reports. The firm owned 15,000 shares of the company’s stock after selling 8,000 shares during the period. AWM Investment Company Inc.’s holdings in argenex were worth $8,268,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ARGX. Franklin Resources Inc. boosted its position in shares of argenex by 103.9% in the 2nd quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock worth $154,233,000 after purchasing an additional 142,606 shares in the last quarter. Millennium Management LLC increased its holdings in shares of argenex by 316.9% during the first quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock valued at $158,977,000 after acquiring an additional 204,180 shares in the last quarter. Jennison Associates LLC raised its position in shares of argenex by 6.1% in the 2nd quarter. Jennison Associates LLC now owns 264,647 shares of the company’s stock valued at $145,879,000 after purchasing an additional 15,186 shares during the last quarter. Orbimed Advisors LLC boosted its stake in argenex by 0.6% in the 2nd quarter. Orbimed Advisors LLC now owns 208,000 shares of the company’s stock worth $114,654,000 after purchasing an additional 1,300 shares in the last quarter. Finally, American Century Companies Inc. grew its position in argenex by 38.3% during the 2nd quarter. American Century Companies Inc. now owns 205,906 shares of the company’s stock worth $113,503,000 after purchasing an additional 57,054 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Trading Down 1.3%

argenex stock opened at $877.94 on Friday. The firm has a market cap of $54.05 billion, a PE ratio of 37.70, a P/E/G ratio of 0.89 and a beta of 0.37. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The stock’s 50 day simple moving average is $863.28 and its two-hundred day simple moving average is $716.27.

argenex (NASDAQ:ARGX) last posted its earnings results on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, beating the consensus estimate of $4.37 by $0.03. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. On average, equities research analysts forecast that argenex SE will post 3.13 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Stifel Nicolaus raised their price target on shares of argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a report on Thursday. Guggenheim restated a “buy” rating and issued a $1,070.00 target price on shares of argenex in a research note on Thursday, September 18th. Wedbush lifted their price target on argenex from $880.00 to $1,000.00 and gave the stock an “outperform” rating in a research report on Friday, November 14th. Royal Bank Of Canada increased their price objective on argenex from $850.00 to $860.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Finally, Citigroup raised their price objective on argenex from $1,041.00 to $1,124.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $968.83.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.